Pfizer: Serious and Non-Serious Adverse Reactions from Post-Marketing Data

APPENDIX 2.2: Cumulative and Interval Summary Tabulation of Serious and Non-Serious Adverse Reactions from Post-Marketing Data Sources
BNT162B2
Cumulative Reporting Period: Through 18-JUN-2022
Interval Reporting Period: 19-DEC-2021 Through 18-JUN-2022
Total Number of Cases: 507,683 (Interval) / 1,485,027 (Cumulative)
Total Number of Adverse Events (PT): 1,591,026 (Interval) / 4,964,106 (Cumulative)
MedDRA Version: v.25.0J